Pluristem receives $470,000 grant from Israel to develop PLX-I stem cell product

By E. Janene Geiss

Philadelphia, Aug. 24 - Pluristem Life Systems, Inc. said Thursday that its fully owned subsidiary Pluristem Ltd received a $470,000 grant from Israel's prestigious Chief Scientist Office.

The royalty-bearing grant is part of the government's Ministry of Trade and Industry program that offers incentives to high-tech companies for capital investment, scientific research and development, according to a company news release.

The grant was designated by the Chief Scientist Office to further develop Pluristem's stem cell product PLX-I, a breakthrough potential solution that could be used to replace the traditional bone marrow transplant search and match process.

"The grant will help us to complete additional animal studies and human clinical trials," Zami Aberman, chief executive officer of Pluristem, said in the release.

Pluristem is a Haifa, Israel, life sciences company developing stem cell expansion technology products to treat blood disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.